Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration
Small cell carcinoma of the esophagus (SCCE) is a rare and highly malignant type of esophageal cancer with no standard treatment, facing challenges of resistance to conventional therapies. This study presents the cases of one extensive-stage and two limited-stage SCCE patients treated with chemoimmu...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2370085 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184498844532736 |
|---|---|
| author | Junhan Wu Xin Xia Longlong Gong Shujie Huang Hongbo Zheng Guibin Qiao Yong Tang |
| author_facet | Junhan Wu Xin Xia Longlong Gong Shujie Huang Hongbo Zheng Guibin Qiao Yong Tang |
| author_sort | Junhan Wu |
| collection | DOAJ |
| description | Small cell carcinoma of the esophagus (SCCE) is a rare and highly malignant type of esophageal cancer with no standard treatment, facing challenges of resistance to conventional therapies. This study presents the cases of one extensive-stage and two limited-stage SCCE patients treated with chemoimmunotherapy. The two limited-stage patients underwent surgery post-treatment and experienced notable and enduring positive responses. This represents the first documented application of neoadjuvant chemoimmunotherapy in limited-stage SCCE patients. Additionally, comprehensive immunohistochemical analysis and whole exome sequencing were performed on the case patients. The findings revealed that infiltration of CD8+ T cells and PD-L1 expression in the SCCE tumor were key factors for favorable responses in SCCE patients receiving chemoimmunotherapy. |
| format | Article |
| id | doaj-art-8df837b925fd4c01b3aa8bb775156311 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-8df837b925fd4c01b3aa8bb7751563112025-08-20T02:17:01ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2370085Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker explorationJunhan Wu0Xin Xia1Longlong Gong2Shujie Huang3Hongbo Zheng4Guibin Qiao5Yong Tang6Shantou University Medical College, Shantou, ChinaDepartment of Thoracic Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaGenecast Biotechnology Co. Ltd, Wuxi City, Jiangsu, ChinaDepartment of Thoracic Surgery, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, ChinaGenecast Biotechnology Co. Ltd, Wuxi City, Jiangsu, ChinaShantou University Medical College, Shantou, ChinaDepartment of Thoracic Surgery, Shenzhen Nanshan People’s Hospital, Shenzhen, ChinaSmall cell carcinoma of the esophagus (SCCE) is a rare and highly malignant type of esophageal cancer with no standard treatment, facing challenges of resistance to conventional therapies. This study presents the cases of one extensive-stage and two limited-stage SCCE patients treated with chemoimmunotherapy. The two limited-stage patients underwent surgery post-treatment and experienced notable and enduring positive responses. This represents the first documented application of neoadjuvant chemoimmunotherapy in limited-stage SCCE patients. Additionally, comprehensive immunohistochemical analysis and whole exome sequencing were performed on the case patients. The findings revealed that infiltration of CD8+ T cells and PD-L1 expression in the SCCE tumor were key factors for favorable responses in SCCE patients receiving chemoimmunotherapy.https://www.tandfonline.com/doi/10.1080/21645515.2024.2370085Small cell carcinoma of the esophagusneoadjuvant chemoimmunotherapyPD-L1CD8+ T cellcase reports |
| spellingShingle | Junhan Wu Xin Xia Longlong Gong Shujie Huang Hongbo Zheng Guibin Qiao Yong Tang Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration Human Vaccines & Immunotherapeutics Small cell carcinoma of the esophagus neoadjuvant chemoimmunotherapy PD-L1 CD8+ T cell case reports |
| title | Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration |
| title_full | Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration |
| title_fullStr | Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration |
| title_full_unstemmed | Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration |
| title_short | Neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus: Clinical efficacy and biomarker exploration |
| title_sort | neoadjuvant chemoimmunotherapy for small cell carcinoma of the esophagus clinical efficacy and biomarker exploration |
| topic | Small cell carcinoma of the esophagus neoadjuvant chemoimmunotherapy PD-L1 CD8+ T cell case reports |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2370085 |
| work_keys_str_mv | AT junhanwu neoadjuvantchemoimmunotherapyforsmallcellcarcinomaoftheesophagusclinicalefficacyandbiomarkerexploration AT xinxia neoadjuvantchemoimmunotherapyforsmallcellcarcinomaoftheesophagusclinicalefficacyandbiomarkerexploration AT longlonggong neoadjuvantchemoimmunotherapyforsmallcellcarcinomaoftheesophagusclinicalefficacyandbiomarkerexploration AT shujiehuang neoadjuvantchemoimmunotherapyforsmallcellcarcinomaoftheesophagusclinicalefficacyandbiomarkerexploration AT hongbozheng neoadjuvantchemoimmunotherapyforsmallcellcarcinomaoftheesophagusclinicalefficacyandbiomarkerexploration AT guibinqiao neoadjuvantchemoimmunotherapyforsmallcellcarcinomaoftheesophagusclinicalefficacyandbiomarkerexploration AT yongtang neoadjuvantchemoimmunotherapyforsmallcellcarcinomaoftheesophagusclinicalefficacyandbiomarkerexploration |